Ongoing Clinical Trials for Ophthalmoplegia
Currently, there is 1 ongoing clinical trial investigating treatments for ophthalmoplegia, specifically focusing on internuclear ophthalmoparesis in patients with multiple sclerosis. This trial is exploring the potential of clemastine fumarate to improve eye movement problems by supporting nerve repair.
Clinical trial locations
- Netherlands
Study on Clemastine and Fampridine for Patients with Multiple Sclerosis and Internuclear Ophthalmoparesis
This clinical trial is investigating whether clemastine fumarate can help improve eye movement problems in people who have both multiple sclerosis and internuclear ophthalmoparesis. Internuclear ophthalmoparesis is a condition that makes it difficult for the eyes to move together properly, often causing double vision or focusing difficulties.
Who can participate:
- Adults between 18 and 70 years of age
- People with a confirmed diagnosis of multiple sclerosis
- Those who have internuclear ophthalmoplegia, confirmed by a special eye movement test called infrared oculography
- Participants can continue using their current disease-modifying therapies for multiple sclerosis
- Individuals who understand the study’s purpose and risks and are willing to provide informed consent
Who cannot participate:
- People without a confirmed diagnosis of multiple sclerosis or internuclear ophthalmoparesis
- Individuals outside the specified age range
- Members of vulnerable populations who may need special protection
What the trial involves:
The main goal of this study is to see if clemastine fumarate can help repair the protective covering of nerves, called myelin, which is often damaged in multiple sclerosis. This repair process is known as remyelination. Participants will take clemastine fumarate tablets by mouth, and some may receive a placebo (an inactive pill that looks like the real medication but contains no active ingredient). Additionally, participants will take Fampyra, another medication used to improve walking in people with multiple sclerosis.
Throughout the study, researchers will measure changes in eye movement using a special test to track the Versional Dysconjugacy Index, which helps assess how well the eyes move together. These measurements will be taken at the beginning of the study and then at several points over the following three years (at 6, 12, 24, and 36 months). The study is expected to be completed by December 31, 2027.
Investigational drug:
The main medication being tested is clemastine fumarate, which is traditionally used as an antihistamine for allergies but is now being explored for its potential to support nerve repair in neurological conditions. By blocking histamine receptors, it may indirectly help restore the protective covering around nerves, potentially improving symptoms like eye movement problems in people with multiple sclerosis and internuclear ophthalmoparesis.
Summary
There is currently one clinical trial available for patients with ophthalmoplegia, specifically those who also have multiple sclerosis and internuclear ophthalmoparesis. This trial is taking place in the Netherlands and focuses on testing clemastine fumarate as a potential treatment to improve eye movement by supporting the repair of damaged nerve coverings. The study represents an innovative approach to addressing eye movement problems that can significantly affect quality of life in people with these conditions. Participants will be followed for up to three years to assess both immediate and long-term benefits of the treatment.